Gallery

Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption

Episode 3: Evaluating the Effects of TSC on Maximal Oxygen Consumption 150 150 Diffusion Pharmaceuticals Inc.

Chief Medical Officer Dr. Chris Galloway previews Diffusion’s Altitude Trial, the second in a trio of Oxygenation Trials that will collectively inform late phase programs and the clinical development plan for lead drug candidate TSC.

Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen

Episode 2: Exploring TSC’s Impact on Tissue-Level Changes in Oxygen 150 150 Diffusion Pharmaceuticals Inc.

Dr. Chris Galloway, Chief Medical Officer of Diffusion, explains the TCOM Trial design, top-line results, and the relevancy of this first of three Oxygenation Trials that together will inform late-phase programs and clinical indications for lead drug candidate TSC.

Diffusion Pharmaceuticals Issues Letter to Shareholders

Diffusion Pharmaceuticals Issues Letter to Shareholders 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference

Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Episode 1: The Science of Solving for Hypoxia

Episode 1: The Science of Solving for Hypoxia 150 150 Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals CEO Robert Cobuzzi, Jr., PhD discusses cellular oxygen deficiency, the TSC development plan, and potential future applications for this small molecule therapeutic with a novel MOA.

Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals

Introducing Fueling Life: a Podcast from Diffusion Pharmaceuticals 150 150 Diffusion Pharmaceuticals Inc.

This podcast will discuss hypoxia, a potentially fatal shortage of oxygen in a body tissue, and cover the development plan for lead product candidate TSC, which enhances oxygen diffusion to hypoxic tissue.

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division

Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy, and Critical Care Division 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 30, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update

Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial

Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum

Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., June 21, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Back to top